ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MCH-Guard: Multimodal machine learning framework for risk stratification of cerebral microhemorrhage risk in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.Molecular neurodegeneration · 2026Article
- The concurrent burden of Alzheimer's pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline.The journal of prevention of Alzheimer's disease · 2026Article
- Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice.bioRxiv : the preprint server for biology · 2026Article
- Development and validation of an interpretable clinical scoring model to monitor the progression of preclinical Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionCerebral amyloid angiopathy (CAA) is associated with an increased risk of amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer's disease using anti-amyloid beta (Aβ) monoclonal antibody drugs. Here, we developed a tool, CAA risk score (CAARS) to predict the severity of CAA neuropathology.
methodsThe National Alzheimer's Coordinating Center (NACC) data were used to develop the CAARS, which was then externally validated using the Religious Orders Study and Memory and Aging Project (ROSMAP) data.
resultsThe CAARS-4 model achieved a mean area under the receiver-operating characteristic (ROC) curve (AUC-ROC) of 0.71 (95% confidence interval [CI]: 0.69-0.72) and a Harrell's generalized C-index of 0.69 (95% CI: 0.68-0.71) in the NACC cohort validation. It outperformed the baseline models, and the promising performance was validated on ROSMAP participants, demonstrating the robustness and generalizability of the model. DISCUSSION: CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow-up studies. HIGHLIGHTS: Cerebral amyloid angiopathy (CAA) severity can only be confirmed postmortem. CAA is associated with an elevated risk of amyloid-related imaging abnormalities (ARIA). The CAA risk score (CAARS) can stratify CAA risks in living patients. Hypertension and apolipoprotein E (APOE) ε4 are risk factors for CAA. The CAARS has the potential to predict risk of ARIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.